All translations
Jump to navigation
Jump to search
Enter a message name below to show all available translations.
Found 2 translations.
| Name | Current message text |
|---|---|
| h English (en) | {| class="wikitable" |+ !Medication Name !Trade name(s) !Mechanism of action !Current FDA Status !placebo-adjusted percent bodyweight lost (highest dose studied) |- |[[Lorcaserin]] |Belviq |[[5-HT2C receptor]] agonist |Withdrawn for safety reasons | 6.25 percent |- |[[Sibutramine]] |Meridia |[[Serotonin–norepinephrine reuptake inhibitor]] |Withdrawn due to cardiovascular risks | 19.7 percent |- |[[Rimonabant]] |Acomplia, Zimbutli |[[Cannabinoid receptor antagonist]] |Withdrawn for safety reasons | {{convert|2.6 to 6.3|kg}} |- |[[Fenfluramine]] | |[[Serotonin releasing agent]] |Withdrawn for safety reasons | - |- |[[Fenfluramine/phentermine]] (fen-phen) |Pondimin | |Withdrawn for safety reasons |13.9 percent |- |[[Dexfenfluramine]] |Redux |[[Serotonin releasing agent]] |Withdrawn for safety reasons |{{convert|3.5|kg}} |- |[[2,4-Dinitrophenol]] | |[[Uncoupling agent]] |Withdrawn for safety reasons |{{convert|17.1|lb}} per patient on average (uncontrolled study) |
| h Japanese (ja) | {| class="wikitable" |+ !医薬品名 !商品名 !作用機序 !現在のFDAステータス !プラセボ調整による体重減少率（最高用量試験） |- |[[Lorcaserin/ja]] |ベルヴィーク |[[5-HT2C receptor/ja]]作動薬 |安全上の理由により中止 | 6.25 % |- |[[Sibutramine/ja]] |メリディア |[[Serotonin–norepinephrine reuptake inhibitor/ja]] |心血管系リスクにより中止 | 19.7 % |- |[[Rimonabant/ja]] |アコンプリア、ジンブトリ |[[Cannabinoid receptor antagonist/ja]] |安全上の理由により中止 | {{convert|2.6 to 6.3|kg}} |- |[[Fenfluramine/ja]] | |[[Serotonin releasing agent/ja]] |安全上の理由により中止 | - |- |[[Fenfluramine/phentermine/ja]] (フェンフェン) |ポンディミン | |安全上の理由により中止 |13.9 % |- |[[Dexfenfluramine/ja]] |リダックス |[[Serotonin releasing agent/ja]] |安全上の理由により中止 |{{convert|3.5|kg}} |- |[[2,4-Dinitrophenol/ja]] | |[[Uncoupling agent/ja]] |安全上の理由により中止 |{{convert|17.1|lb}} 患者1人当たり平均（非対照試験） |